Trinity Biotech stock: RedChip covers Trinity Biotech stock after 43 percent growth

Published on 10/24/2026 at 03:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gross margin reached 35.40 percent in the first quarter, up from 25.20 percent. For Trinity Biotech stock, revenue reached USD 10.80 million.

Growth reaches diagnostics

RedChip highlighted 43.00 percent first-quarter revenue growth on October 12, 2026.
Gross margin reached 35.40 percent in the first quarter from 25.20 percent.
Trinity Biotech had a market capitalization of USD 147.8 million as of October 24, 2026.

TRIB, US8964385046, Illustration mit AI erstellt.

Trinity Biotech plc (ISIN US8964385046) reported first-quarter 2026 revenue of USD 10.80 million, a 43.00 percent year-over-year increase. According to X on October 12, 2026, RedChip highlighted the revenue growth and a stronger gross margin as part of its coverage of the company.

What does 43 percent growth change?

The first-quarter margin reached 35.40 percent, compared with 25.20 percent a year earlier, according to the same RedChip coverage. The combination points to a sharper improvement in production economics than the revenue figure alone suggests.

Trinity Biotech remains centered on diagnostics and diabetes management. Its investor-relations overview says the company sells diagnostic systems, reagents and instrumentation in more than 100 countries, while it is also developing continuous glucose monitoring products through acquired biosensor assets. The company announced orders for more than two million TrinScreen HIV tests on June 16, 2026, according to its Trinity Biotech investor-relations page.

Diagnostics remain the core test

The operating picture still carries a sharp profitability risk. Finance data show fiscal-year 2025 revenue of USD 43.79 million and a net loss of USD 37.38 million, making the first-quarter margin improvement an early operating signal rather than a completed turnaround.

The Nasdaq quote stood at USD 7.30 on October 23, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 5.01 to USD 52.50, while market capitalization was USD 147.8 million as of October 24, 2026.

Stock valuation and business scale

Trinity Biotech is a healthcare company in the medical-specialties industry. Its business combines established infectious-disease and diabetes diagnostics with newer biosensor and data-center cooling initiatives, leaving execution and commercialization as the central investor questions.